Tagged as: PharmaCare

British Columbia Announces Coverage of Three New Biosimilars for Blood Clot Prevention and Treatment

On March 22, British Columbia’s Ministry of Health announced that three new enoxaparin biosimilars, Valero Pharmaceuticals’ REDESCA, Juno Pharmaceuticals’ , and Sandoz’s INCLUNOX, would be covered by PharmaCare, the province’s public health plan.  Enoxaparin is a blood thinner that is used for the prevention and treatment of blood clot disorders. …

Read More

British Columbia Expands Biosimilar Initiative to Rapid-Acting Insulins

On December 1, 2021 the government of British Columbia announced that it is further expanding its biosimilar initiative.  The statement reported that as of November 30, 2021 an estimated 30,000 patients on the rapid-acting insulin lispro (Humalog) and insulin aspart (NovoRapid) would have six months to transition to the respective…

Read More